Abstract:BACKGROUND: Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer worldwide. Until now, the molecular mechanisms underlying LUAD progression have not been fully explained. This study aimed to construct a competing endogenous RNA (ceRNA) network to predict the progression in LUAD. METHODS: Differentially expressed lncRNAs (DELs), miRNAs (DEMs), and mRNAs (DEGs) were identified from The Cancer Genome Atlas (TCGA) database with a vertical bar log(2)FC vertical bar > 1.0 and a false discovery rate (FDR) < 0.05. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), protein-protein interaction (PPI) network, and survival analyses were performed to analyse these DEGs involved in the ceRNA network. Subsequently, the drug-gene interaction database (DGIdb) was utilized to select candidate LUAD drugs interacting with significant DEGs. Then, lasso-penalized Cox regression and multivariate Cox regression models were used to construct the risk score system. Finally, based on the correlations between DELs and DEGs involved in the risk score system, the final ceRNA network was identified. Meanwhile, the GEPIA2 database and immunohistochemical (IHC) results were utilized to validate the expression levels of selected DEGs. RESULTS: A total of 340 DELs, 29 DEMs, and 218 DEGs were selected to construct the initial ceRNA network. Functional enrichment analyses indicated that 218 DEGs were associated with the KEGG pathway terms "microRNAs in cancer", "pathways in cancer", "cell cycle", "HTLV-1 infection", and the "PI3K-Akt signalling pathway". K-M survival analysis of all differentially expressed genes involved in the ceRNA network identified 24 DELs, 4 DEMs, and 29 DEGs, all of which were significantly correlated with LUAD progression (P < 0.05). Furthermore, 15 LUAD drugs interacting with 29 significant DEGs were selected. After lasso-penalized Cox regression and multivariate Cox regression modelling, PRKCE, DLC1, LATS2, and DPY19L1 were incorporated into the risk score system, and the results suggested that LUAD patients who had the high-risk score always suffered from a poorer overall survival. Additionally, the correlation coefficients between these 4 DEGs and their corresponding DELs involved in the ceRNA network suggested that there were 2 significant DEL-DEG pairs, NAV2-AS2 - PRKCE ( r = 0.430, P < 0.001) and NAV2-AS2 - LATS2 ( r = 0.338, P < 0.001). And NAV2-AS2 - mir-31 - PRKCE and NAV2-SA2 - mir-31 - LATS2 were finally identified as ceRNA network involved in the progression of LUAD. CONCLUSIONS: The lncRNA-miRNA-mRNA ceRNA network plays an essential role in predicting the progression of LUAD. These results may improve our understanding and provide novel mechanistic insights to explore prognosis and therapeutic drugs for LUAD patients.

Integrative analysis of ceRNA network reveals functional lncRNAs associated with independent recurrent prognosis in colon adenocarcinoma

Integrative Analysis and Identification of an Excellent Lncrna Signature to Predict Prognosis in Patients with COAD

A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures

Prognosis prediction model based on competing endogenous RNAs for recurrence of colon adenocarcinoma

A 6 lncRNA-Based Risk Score System for Predicting the Recurrence of Colon Adenocarcinoma Patients

Integration analysis for novel lncRNA markers predicting tumor recurrence in human colon adenocarcinoma

Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer

Expression Analysis of Lncrna As Prognostic Biomarkers in Colon Adenocarcinoma

A Competing Endogenous RNA Network Reveals Novel Potential Lncrna, Mirna, and Mrna Biomarkers in the Prognosis of Human Colon Adenocarcinoma.

Comprehensive Investigation of a Novel Differentially Expressed Lncrna Expression Profile Signature to Assess the Survival of Patients with Colorectal Adenocarcinoma.

Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma.

Integrated analysis of lncRNA associated-competing endogenous RNAs as prognostic biomarkers in clear cell renal carcinoma.

Construction of a Novel MYC-Associated ceRNA Regulatory Network to Identify Prognostic Biomarkers in Colon Adenocarcinoma

Integrated analysis of long noncoding RNA associated-competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma

Analysis of Lncrna-Mediated Cerna Crosstalk and Identification of Prognostic Signature in Head and Neck Squamous Cell Carcinoma.

Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network

Identification of Key Novel lncRNAs RP11-400N13.3 and RP11-197K6.1 that Construct ceRNA Networks Associated with Recurrence and Metastasis in Colon Cancer

Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic lncRNA Signature in Bladder Cancer

Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.

Identification and development of long non-coding RNA-associated regulatory network in colorectal cancer.

Identification of mRNA-miRNA-lncRNA Competing Endogenous RNA Network in Adrenocortical Carcinoma Using Bioinformatics Analysis